Natera, INC Form 4 insider transactions
NASDAQ
NTRA
Natera, INCNatera's Executive Chairman, Matthew Rabinowitz, sold 1,718 shares of common stock for $139.8083 per share to cover tax obligations related to RSU vesting, as disclosed in a Rule 10b5-1(c) plan.
NASDAQ
NTRA
Natera, INCNatera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,206 shares of common stock to cover tax withholding related to RSU vesting, as part of a Rule 10b5-1 plan.
NASDAQ
NTRA
Natera, INCNatera's President and Chief Business Officer, John Fesko, sold 1,710 shares of common stock to cover tax obligations related to RSU vesting.
NASDAQ
NTRA
Natera, INCNatera's SEC and Chief Legal Officer, Daniel Rabinowitz, sold 1,994 shares of common stock to cover tax obligations related to RSU vesting, as disclosed in a recent Form 4 filing.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Brinkley Ruth Williams received 112 shares of common stock through Restricted Stock Units as compensation for board service, aligning her interests with shareholders.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Herm Rosenman acquired 153 shares of common stock through Restricted Stock Units as part of his quarterly retainer fees.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Gail Boxer Marcus acquired 141 fully vested Restricted Stock Units as compensation for Board service, aligning her interests with shareholders.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Roelof Botha acquired 173 shares of common stock through a Restricted Stock Unit grant in lieu of quarterly retainer fees.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Monica Bertagnolli was issued 108 fully vested Restricted Stock Units as compensation for her board service, increasing her direct beneficial ownership to 5,128 shares.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Roy D. Baynes acquired 108 shares of common stock through a fully vested Restricted Stock Unit grant on July 25, 2025, increasing his total beneficial ownership to 18,266 shares.
NASDAQ
NTRA
Natera, INCNatera's Chief Financial Officer, Michael Burkes Brophy, reported multiple stock transactions including the vesting of Restricted Stock Units and subsequent sales, primarily under a pre-arranged 10b5-1 trading plan and for tax obligations.
NASDAQ
NTRA
Natera, INCNatera's Chief Financial Officer, Michael Burkes Brophy, exercised Restricted Stock Units and subsequently sold a portion of the resulting common stock to cover tax withholding obligations.
NASDAQ
NTRA
Natera, INCNatera, Inc. CEO Steven Chapman reported the vesting of 3,386 Restricted Stock Units and a subsequent sale of 1,622 shares to cover tax obligations.
NASDAQ
NTRA
Natera, INCNatera's SEC and Chief Legal Officer, Daniel Rabinowitz, executed multiple stock sales totaling over $3.4 million in June and July 2025, primarily under a Rule 10b5-1 trading plan.
NASDAQ
NTRA
Natera, INCNatera Co-Founder and Director Jonathan Sheena reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, executed under a pre-arranged trading plan.
NASDAQ
NTRA
Natera, INCNatera's President of Clinical Diagnostics, Solomon Moshkevich, sold shares totaling approximately $299,096 to cover tax withholding obligations related to RSU vesting.
NASDAQ
NTRA
Natera, INCNatera's President and Chief Business Officer, John Fesko, executed two pre-planned sales of common stock totaling 1,777 shares to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director and Co-Founder Jonathan Sheena has filed a Form 4 indicating a future sale of 3,070 shares of common stock on July 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director and Co-Founder Jonathan Sheena sold 3,000 shares of common stock on July 2, 2025, through pre-arranged Rule 10b5-1 trading plans.
NASDAQ
NTRA
Natera, INCNatera, Inc. CEO and President Steven Leonard Chapman sold 5,343 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
NTRA
Natera, INCNatera, Inc.'s President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
NTRA
Natera, INCA Natera, Inc. director exercised stock options and subsequently sold an equivalent number of common shares on July 1, 2025, under a pre-arranged 10b5-1 trading plan.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Brinkley Ruth Williams was granted 2,143 restricted stock units, increasing her beneficial ownership to 5,107 shares.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Herm Rosenman was granted 2,414 restricted stock units (RSUs) on June 27, 2025, as part of his compensation, aligning his interests with long-term shareholder value.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Gail Boxer Marcus acquired 2,414 Restricted Stock Units (RSUs) as part of her compensation, aligning her interests with long-term shareholder value.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Roelof Botha was granted 2,414 Restricted Stock Units (RSUs) on June 27, 2025, aligning his interests with long-term shareholder value.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Monica Bertagnolli acquired 2,143 restricted stock units, increasing her direct beneficial ownership to 5,020 shares.
NASDAQ
NTRA
Natera, INCNatera, Inc. Director Roy D. Baynes was granted 2,143 restricted stock units, increasing his direct beneficial ownership to 18,158 shares.
NASDAQ
NTRA
Natera, INCMatthew Rabinowitz, Executive Chairman of Natera, Inc., reported the sale of 44,000 shares of common stock through a Rule 10b5-1 trading plan, with transactions occurring between May 15 and June 13, 2025.
NASDAQ
NTRA
Natera, INCNatera, Inc. Co-Founder and Director Jonathan Sheena reported the sale of 6,070 shares of common stock for approximately $1 million through pre-arranged trading plans.